title: [Preclinical and clinical researches of lenvatinib mesylate (Lenvima capsule), a novel antitumor agent approved for thyroid cancer treatment].
authors.forename: Akihiko
authors.initials: A
authors.lastname: Tsuruoka
authors.forename: Junji
authors.initials: J
authors.lastname: Matsui
authors.forename: Takuya
authors.initials: T
authors.lastname: Suzuki
authors.forename: Noriyuki
authors.initials: N
authors.lastname: Koyama
authors.forename: Tatsuo
authors.initials: T
authors.lastname: Watanabe
authors.forename: Yasuhiro
authors.initials: Y
authors.lastname: Funahashi
mesh_terms: D020533:Angiogenesis Inhibitors / Q000737:chemistry / Q000627:therapeutic use*; D000818:Animals; D000970:Antineoplastic Agents / Q000737:chemistry / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D006801:Humans; D010671:Phenylurea Compounds / Q000737:chemistry / Q000627:therapeutic use*; D047428:Protein Kinase Inhibitors / Q000737:chemistry / Q000627:therapeutic use; D011494:Protein Kinases / Q000737:chemistry / Q000378:metabolism; D011804:Quinolines / Q000737:chemistry / Q000627:therapeutic use*; D013964:Thyroid Neoplasms / Q000188:drug therapy*
chemical_list: D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents; D010671:Phenylurea Compounds; D047428:Protein Kinase Inhibitors; D011804:Quinolines; D011494:Protein Kinases; C531958:lenvatinib